Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

6 evidence topics · 5 sources

U.S. prevalence of previously treated ER-positive HER2-negative advanced disease

No evidence found.

Worldwide 5-year prevalence of breast cancer by continent, GLOBOCAN 2024